Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Fidelio Capital in connection with the establishment of its largest fund to date
Mandate

Vinge has advised Fidelio Capital in connection with the establishment of its largest fund to date

June 08, 2023 Employment and Benefits Banking and Finance Corporate Tax Private Funds M&A

The fund – which is Fidelio Capital’s third – has secured more than EUR 1 billion in total capital commitments from an international investor base, which is more than triple the size of the total capital commitments of its previous investment mandate.

Fidelio Capital was founded by Gabriel Fitzgerald in 2010 and focuses on investments in companies without being limited by a pre-determined investment horizon or geographical border, in which it can be an active owner. Through its investment strategy, Fidelio Capital has generated market leading returns, with an average gross IRR of 80% since inception.

Vinge’s team primarily consisted of Mattias Schömer, Jonas Bergström, Jesper Ottergren, Martin Cronsioe, Viveka Classon, Malin Malm Waerme, Fredrik Dahl, Anton Sjökvist, Emelie Svanberg, Semir Omerbasic and Viktoria Wnuk.

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026